Stockscreener 앱 받기
0.00
100.00%
-0.735
시간 외 거래:
.29
0.29
+
전일 마감가:
$0.735
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$N/A
수익:
$1.40M
순이익/손실:
$-3.78M
주가수익비율:
0.00
EPS:
-1.4649
순현금흐름:
$-1.74M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-96.88%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$0.735
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Compare ATXI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.00 | 0 | 1.40M | -3.78M | -1.74M | -1.4649 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 115.27B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 80.00B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 43.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 43.52B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 30.74B | 5.36B | 287.73M | 924.18M | 2.5229 |
Avenue Therapeutics Inc 주식(ATXI)의 최신 뉴스
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - msn.com
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan
Turn Therapeutics secures $25M loan facility from Avenue Capital - investing.com
Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering - Sahm
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - marketscreener.com
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering - Sahm
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
Neurology stocks rebound in 2025 after midyear slump - BioWorld MedTech
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
Tangible book value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Net current asset value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights
Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
ATXI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Avenue Therapeutics to develop add-on Pompe disease treatment - Pompe Disease News
Avenue Therapeutics Licenses ATX-04 for Pompe Disease - The Globe and Mail
Avenue Therapeutics licenses ATX-04 for Pompe disease treatment By Investing.com - Investing.com Australia
Avenue Therapeutics (OTC: ATXI) licenses ATX-04 Pompe therapy from Duke - Stock Titan
Avenue Therapeutics licenses ATX-04 for Pompe disease treatment - Investing.com
After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan
Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire
Rare muscle disease drug deal: Avenue backs ATX-04 for Pompe - Stock Titan
Lion Street Advisors LLC Buys 5,619 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Candel Therapeutics Announces Pricing of Public Offering - The Manila Times
Ikarian Capital discloses 4.1% Avenue Therapeutics (ATXI) stake in 13G/A - Stock Titan
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen - MarketBeat
Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat
Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded by Wall Street Zen to Sell - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street - The Joplin Globe
Axsome Therapeutics says AXS-12 NDA submission on track for January - MSN
Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Raised to "Buy" at Wall Street Zen - MarketBeat
TMC the metals (NASDAQ:TMC) vs. Canadian Zeolite (OTCMKTS:IZCFF) Critical Review - Defense World
Analyzing Turn Therapeutics (TTRX) & The Competition - Defense World
HCA Healthcare (NYSE:HCA) Shares Gap Up After Earnings Beat - Defense World
Boku (LON:BOKU) Insider Jonathan Peter Prideaux Sells 325,000 Shares of Stock - Defense World
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - Morningstar
Avenue Therapeutics Inc (ATXI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.03%
2.20%
자본화:
|
볼륨(24시간):